CeriBell, Inc. (CBLL) Earnings Call Transcript
November 4, 2025
Earnings Call Speaker Segments
Thanks, Brian. Good afternoon, everyone, and I appreciate you all being here for our call regarding third quarter 2025 earnings. It's a pleasure to share news of yet another robust quarter, as we keep delivering on our main growth programs while strengthening our standing as the leader in the point-of-care EEG category; we've kept broadening patient access via new accounts and higher utilization, all while pushing forward our strong product pipeline. We feel these efforts' strength is unmistakably shown in what we achieved. Revenue totaled $22.6 million during the third quarter of 2025. That's 31% growth compared with the prior-year period and represents our 30th straight quarter of sequential top-line expansion. What drove this performance was the dependable, recurring character of our business model plus ongoing excellence in commercial execution to bring on new accounts and boost usage. With these trends and the momentum going into the quarter's end, our confidence in the core commercial strategy remains firm, and we're lifting our revenue outlook for the entire 2025 year. We now anticipate bringing in between $87 million and $89 million for full year 2025, equal to 34% growth year over year at the midpoint. What we've accomplished so far stems from both solid commercial execution and the groundwork laid to capture what we see as a $2 billion market opportunity that's immediately addressable. Our main aim is making point-of-care EEG the new standard of care for seizure management in acute care; in our view, every ICU and emergency department ought to have the Ceribell system and the advantages our solution offers. This need is urgent and deep. Approximately 3 million patients across the U.S. face seizure risk in acute care settings. A large number of them will endure lengthy diagnostic delays with conventional EEG, waiting hours or possibly days. Some might not get monitoring whatsoever because of constrained EEG access or insufficient clinical awareness. The fallout is serious, since seizures that go prolonged and untreated can cause severe, permanent brain damage or death. By contrast, the SAFER-EEG clinical trial demonstrated that the Ceribell system cuts median time to EEG by 19 hours, and lowers patients' severe disability rate by 18%. Meanwhile, those given antiseizure medication without EEG confirming seizures, relying on observation alone, could face needless risks such as incubation and longer ICU stays. The Ceribell system has demonstrated it can achieve a median reduction in ICU length of stay of 4.1 days. In the end, patients' lives and quality of life hang in the balance, and we think our platform can make care more timely and suitable. Getting these patients the care they require begins with efforts to bring the Ceribell system to hospitals throughout the U.S. Toward that goal, we've consistently achieved solid progress in growing our account base. As of September 30, we had 615 active accounts. That represents a gain of 31 accounts compared with the quarter before, marking our biggest quarter-over-quarter rise since the company went public; at the same time, we keep extending our footprint into more sites of care. In pursuit of that, we obtained FedRAMP High Authorization during Q2 of this year, which opens the door to roughly 200 hospitals in the VA network. We're happy to share that after a pilot that recently went well, the VA system has told us it plans to broaden its use of the Ceribell system even more over the quarters ahead. While we move into new facilities across the country, we're likewise partnering with existing customers to boost usage and widen access throughout departments and patient groups. What we've done so far has paid off, with utilization for each account climbing almost threefold across the last 5 years. Even so, we estimate penetration within our active account base stands at just 30%, which leaves plenty of space to keep growing. Our strongest accounts show what EEG solutions can achieve, in our view. Among our top 10% accounts, usage runs about 3x what comparable-sized average accounts see, and those leading accounts haven't stopped growing. That tells us more than 5,000 hospitals still lack a point of Clarity seizure detection, which echoes what physicians keep telling us. The more EEG you perform, the more seizures you find. Through ongoing training and education, clinical evidence generation, protocol development, and growth into additional departments such as the ED, we intend to help these top accounts replicate and scale their best practices. Leading that push is our CAM team, and it's already well underway. Last, past the adult population, we keep putting investment into widening access for pediatric and neonatal groups. In the early part of this year, Clarity received 510(k) clearance for pediatric use, making it the sole seizure detection algorithm cleared for patients 1 year and older. We're building that market through our ongoing pilot of pediatric Clarity among current accounts and children's hospitals, with a full launch expected next year. Strong clinical data behind our product gives us that confidence. In September, we were glad to see an abstract presented at the Neurocritical Care Society Annual Meeting documenting technical validation of pediatric Clarity. That retrospective study looked at how Clarity performed in spotting suspected status epilepticus among 645 pediatric patients between the ages of 1 and 17. Findings showed sensitivity of 94.4%, specificity of 93.1%, and a negative predictive value of 99.8%. What we've found indicates Clarity is able to reliably track suspected status epilepticus among pediatric individuals aged beyond 1 year, delivering prompt, practical direction to the care team at the bedside. Thanks to our AI-based method for developing products, we anticipate that these results — already outstanding — will keep getting better as we grow our database and keep honing our algorithms. We're likewise still dedicated to broadening access to our system for the neonatal population, and we've already created a headcap suited to this vulnerable group of patients. Development of a neonatal version of Clarity remains on schedule, and we expect to launch it in 2026. Meanwhile, we've opened several sites that use the hardware without Clarity, and we're carrying out focused market development work to gain a deeper understanding of the particular characteristics of neonatal patients. Such investments strengthen our mission of helping make point-of-care EEG a new standard of care for detecting seizures in acute care, serving every patient everywhere. We also projected that adding pediatric and neonate products might grow our present addressable market opportunity of $2 billion by roughly $400 million. We perceive an enormous growth runway as we pursue our mission. We'll keep investing in evidence generation, product improvements, provider education and replicating the best practices seen at top-performing centers. Taken together, these investments, along with our established advantages, give us strong confidence in our capacity to bolster our standing as the category leader and a trusted partner for rapid EEG and seizure detection and monitoring.
Before handing things over to Scott, I'd like to spend a moment on the second horizon of our vision, which is establishing EEG as a new vital sign in acute care. To get there, we need to build a multimodal system capable of becoming a routine element of care for every patient who faces risk from various neurological abnormalities. Our approach is to broaden what we can detect into additional conditions, delirium and stroke among them. The innovation area closest on our horizon is pushing forward our delirium algorithm. We're happy to report that our development timeline remains solidly on track. As a reminder, no diagnostic device is commercially available in this market, even though delirium is a widespread and difficult condition affecting more than 30% of patients in the ICU. We're delighted by the progress made so far and expect to lay out a fuller picture of the opportunity, along with our related commercial strategy, over the next several quarters. It matters that our enthusiasm about potential new indications like delirium ties directly to our mission of helping make point-of-care EEG the standard of care. Because the Ceribell system has been broadly adopted for seizure detection across our market, we have the installed base, the data, the trust, the contractual relationships, the security clearances, and the sales infrastructure needed to quickly develop and roll out new algorithms. In our view, these new algorithms will substantially grow our total addressable market by bringing badly needed solutions to new patient populations. We also anticipate creating synergistic value by enabling simultaneous monitoring of patients who face risk from multiple overlapping conditions. Consequently, beyond opening the door to new patients, these pipeline products should drive utilization directly within our installed base. We expect them to act as a powerful growth engine for years ahead, all while mostly leveraging the sales infrastructure we already have. To wrap up, I feel tremendous pride in what we accomplished this quarter. More than 600 hospitals have adopted Ceribell, and our team continues to make meaningful strides in going deeper within those accounts. Even so, we are still quite early in our journey toward making point-of-care EEG the standard of care in the $2 billion U.S. seizure detection market. Right now, roughly 10% of hospitals delivering acute care services in the U.S. use us. That leaves more than 5,000 hospitals without a point-of-care EEG solution that we believe could benefit from our technology. Among the customers we do serve, we estimate penetration of only about 30% for patients requiring timely seizure detection. Put together, this indicates that we've reached only about 3% penetration of our core U.S. market. Our goal is to go deeper and wider in serving the unmet needs of the remaining 97%, through both continued commercial efforts and investments aimed at extending the life-changing benefits of the Ceribell system to additional patient populations. That covers watching over newborns and children as patients too, and that alone opens up an added market chance worth roughly $400 million, possibly by 2025. At the same time, we're pushing past seizures. We've achieved genuine strides in opening up delirium and stroke; in our view, these two indications add up to an opportunity for market growth in the billions of dollars, and they stand as the bedrock of what we're trying to do — turning EEG into a fresh vital sign. So with that said, I'll hand things over now to Scott Blumberg, who serves as our CFO, so he can walk through our results for the third quarter along with what we expect for the rest of 2025.
Thanks, Jane, and good afternoon to all of you. As Jane pointed out, our total revenue in Q3 2025 came to $22.6 million, which is up 31% from $17.2 million in the third quarter of 2024. Growth was mainly fueled by greater uptake of the Ceribell system among both new and existing accounts. Product revenue in Q3 2025 reached $17 million, up 28% compared with $13.3 million in the same quarter of 2024. Subscription revenue for Q3 2025 totaled $5.6 million, an increase of 44% over $3.9 million in Q3 2024; during the quarter, we kept driving deeper penetration within our accounts, raising usage per account on a year-over-year basis. We managed this even though Q3 2024 saw unusually heavy purchasing relative to usage, which created excess product revenue in that comparison period. Keep in mind that we generally experience lower usage in Q2 and Q3 compared with Q1 and Q4, because ICU census tends to drop during the summer months. Gross margin in Q3 2025 was 88%, versus 87% a year earlier. As we head into Q4, I want to note that we'll start shifting to inventory obtained after higher tariffs took effect on goods made in China. Even so, we anticipate keeping gross margins within the mid-80% range during Q4. As we mentioned last quarter, we took proactive measures this year to set up another manufacturing line in Vietnam, and it is now running at full capacity. That lowers our exposure to China-based tariffs and puts us in position to gain from potentially more favorable trade policies. Going forward, we think the steps taken this year to reinforce our supply chain and build resilience have us on track to achieve gross margins in the mid-80% range for the full year 2026, assuming the currently proposed tariffs stay unchanged. Total operating expenses in Q3 2025 were $34.6 million, up 39% from $24.9 million in Q3 2024. Noncash stock-based compensation expense came to $3.3 million in Q3 2025. 5 The rise in operating expense was mainly due to investments in our commercial organization, added headcount to support business growth, legal expenses and costs tied to operating as a public company. Sales and weighted marketing expenses rose $1.1 million in Q3 versus Q2. That sequential increase came from salary and commission expenses related to headcount expansion in Q3, along with the full-quarter impact of headcount added in Q2. Net loss was $13.5 million in Q3 2025, or a loss of $0.37 per share, compared with a loss of $10.4 million, or a loss of $1.85 per share, in Q3 2024. An average weighted share count of 36.8 million shares was used to calculate loss per share for Q3 2025. Our cash, cash equivalents and marketable securities as of September 30, 2025, stood at $168.5 million. Earlier today, we submitted a shelf registration statement on Form S-3 to the SEC, since we just became eligible for that after hitting the 1-year mark since our IPO. This is purely routine corporate housekeeping — it keeps our options open. To be clear, though, we have no plans to go after any financing transaction right now. We're still dedicated to reaching cash flow breakeven using the cash we have, and the strength of our balance sheet makes us quite confident we can get there without bringing in more capital. Now, on to what we expect for the rest of 2025. Because of the momentum we saw in the third quarter of 2025, we now anticipate full year 2025 revenue landing between $87 million and $89 million, which is up from the $85 million to $88 million we guided to previously — that works out to annual growth of 33% to 36% over 2024. We keep growing our base of active accounts and have a very robust backlog of accounts that have sent in purchase orders to adopt the Ceribell System. We don't give guidance on our account base, but it's worth mentioning that we plan to keep up a practice that started in 2023, where we hold off on launching new accounts during the second half of December. That decision comes from what we've learned historically — it's better to steer clear of launching over the holidays, since we've observed that uninterrupted attention to a high-quality launch is required to get the most usage in the first few weeks after launch, and we think that's essential for building healthy long-term utilization rates. With that, I'll hand the call back over to Jane.
Thanks, Scott, and I appreciate everyone taking the time to join us today. To wrap up, I'm quite happy with how we performed in the third quarter and with how our team keeps pushing forward on efforts that will let us achieve the wider strategic vision we've set out. I want to express my gratitude to our employees, to our customers, and to the patients we serve, since they make it possible for us to keep pursuing our mission of helping save lives while also creating significant value for our stakeholders. Last, we're grateful for your support and your ongoing interest in Ceribell. We're eager to share updates about our progress in the quarters ahead. At this point, I'll hand the call over to the operator for any Q&A. Operator?
Congratulations, everyone. Perhaps to kick things off, just regarding 2026 — I'm wondering whether you've got any initial perspectives at this point, particularly around account additions, utilization, and pricing, especially given that the NTAP is set to expire next year?
I'll handle that one. Travis, we aren't offering any commentary about 2026. Naturally, we'll give guidance on the upcoming call. I believe the business's fundamentals and the growth sources when it comes to bringing on new accounts and encouraging usage are going to stay our steady drivers. When it comes to pricing, we've observed an extremely high level of consistency in pricing within our Headband during this year. We've noticed a rise in the Clarity ASP as we've pushed additional recorders into sites that already exist, and we expect to keep up strong discipline as we consider pricing moving forward.
All right, that makes sense. Then perhaps I could ask about the neonatal opportunity. I appreciate everything that was shared during the call. But as you consider bringing that to market, maybe give us a bit more detail on what a full launch in '26 would look like. Also, is it necessary to bring on new accounts that are neonatal accounts? Or do you instead expand further within your existing accounts so things can move more quickly? I'm just trying to understand how that launch and rollout would actually happen.
Yes. The brief response is that it involves both — opening new accounts via neonatal, and existing accounts too. Of the roughly 850 Level 3 and Level 4 NICUs nationwide, about 200 NICUs are already part of our installed base. So with regard to those 200 NICUs, it would be more of a departmental expansion. That's why we place it more within the growth category of same-store growth that drives utilization. Beyond that, there are 2 distinct market segments. One is the other — the 280 children's hospitals. Right now we have barely any presence in children's hospitals, which isn't surprising given that our product is heavily adult focused. So that represents more new account acquisition. Even past children's hospitals, we've initially observed strong interest from NICU through particularly Level 3 community hospitals, which frequently must transfer patients out because they lack EEG; so we also expect that NICU can drive new account addition thanks to strong support from NICU.
Congratulations on the strong quarter. I have two questions. First, I'd like to ask about how far you've gotten when it comes to getting into accounts and teaching the various parts of the hospital. I realize that during the prior year, you devoted considerable time and attention to constructing the model so that fresh accounts could scale in a steady, lasting way — so how is that going, and what kind of pull are you seeing?
Right. What I'd say is that the wins we're seeing build on what we've already observed over time. You can tell that we keep pushing not only to bring in accounts but to drive usage as well. To be specific, during this year we introduced several programs where results have been positive. The first one — Scott touched on it quickly — is that we began urging the team, and they've done well, to place additional recorders into accounts we already have, which frequently results in more departments adopting our device. So a very tight link shows up between expansion and those programs. The second program we launched, whose effects are starting to appear this year, and which we expect to deliver still greater effects in the year ahead, involves collaborating with physicians on protocolization of the patient population. That has worked particularly well for cardiac arrest or post-hemorrhagic stroke, both of which the guideline clearly recommends. Since hospitals don't necessarily revise their guideline each quarter — usually it happens annually — we can — we expect that in the coming year we'll keep seeing growth in that area. The remaining program centers more on ongoing education for physicians and nurses alike, plus sustained quarterly engagement with the administrator, so that rather than merely presenting the economic value Ceribell delivers in theory, we use their very own clinical data to demonstrate the economic value.
Okay. Perhaps a question regarding costs. Based on the guidance, your sales and marketing plus R&D exceeded the increase in revenue. I understand you'll address 2026 during the Q4 earnings call; but what's your perspective on how revenue and operating expenses will grow relative to each other, both near term and over the medium term? And how do you feel about where you stand on reaching cash flow breakeven?
Yeah. I believe we entered this year having completed a successful IPO that brought in more capital than we had planned, and a significant share of those funds went toward building out our commercial infrastructure. Our model works in such a way that the effect shows up later. So the way sales and marketing growth this year relates to revenue reflects that dynamic — you spend first, and the results follow. Naturally, we'll keep seeking ways to expand. However, as we currently see it, at least when it comes to acquiring accounts, the magnitude of growth we experienced during the past year would likely be smaller next year. Consequently, I'd anticipate that growth will ease somewhat in that area. And the investments we've made this year ought to begin producing results as we move into 2026. Regarding cash, given an 88% gross margin and fairly solid command over our spending — which is almost completely linked to growth and only minimally to upkeep — we retain the ability to keep adjusting our investment approach so that we always remain secure with an adequate cash cushion.
Could you begin by perhaps discussing a bit how utilization has increased among accounts based on how long they've been with you, particularly the ones where you've mentioned certain programs aimed at setting up protocols at accounts where EGs ought to be administered according to patient versus ID guidelines? Are those sorts of older, longer-standing accounts seeing steady rises in utilization? I'm just sort of wondering — the question focuses more on your accounts with more tenure. Has the uptick in utilization been fairly steady? Just to figure out whether that's a solid indicator for future growth as your newer accounts get up to speed?
Yes. Thanks, Brandon. A number of factors sit behind the expansion we've observed from accounts with longer tenure or our biggest ones, and we believe a lot of those factors will keep fueling both the top ones, or simply all the remaining accounts. The foremost factor is the one you already mentioned, namely the external guidelines. The stroke — the guideline for managing seizures in the stroke population was released during 2022 and 2023. The cardiac guideline was released at the close of 2019. So — and then COVID happened; so, there are quite a few — many hospitals have still not completely embraced this guideline. With our top account growth, what we frequently observe is that hospitals begin, as time passes, implementing one protocol after another, first cardiac rest, then ICH patient. So that's an ongoing factor. And even among our top accounts, I'd say not every single population group has fully adopted the protocol yet. That's the reason we expect to keep seeing growth there. The next factor is expansion across departments. Even our longest-tenured accounts or our highest-usage accounts aren't present in every single department yet. They could be in all the ICUs and ED, but they might not yet be in the step-down units or in the — on the floor alongside the rapid response nursing team; and naturally, once we begin launching pediatric and neonate, there will be additional departmental expansion. The third factor, I'd say, stems more from how we execute internally. We recognize that not every provider has been trained, even if they may have missed the initial training amid the site initiation turnover, particularly on the night shifts. So, our CAM team has genuinely invested a great deal of effort beyond what's required and stays until late hours to train the night shifts, and that isn't 100% finished yet. So those are a few examples, likely the leading factors behind how our tenured accounts have been growing, and we see the account — these factors don't apply only to tenured accounts, but to all our accounts.
All right. Excellent; and following up on that, I believe, Jane, you were sort of hinting at this, yet you gave a fascinating remark during the prepared remarks that just 30% of accounts — or rather, within your existing accounts, adoption sits at only 30%. Does moving deeper into your existing accounts depend heavily on implementing these protocols? And then, as you mentioned, expanding into new wings. So how is that accomplished? Where does the friction arise when entering those new wings? And then one separate follow-up, if I may add it. Near the end of last week, I believe you received a new 510(k) clearance for the headcap. Any thoughts regarding how significant that clearance is?
Yes. I mean, regarding departmental expansion and protocolization, execution accounts for most of it. I think, when we consider what possible obstacles exist, they include both resources on our side and frequently resources at the — or the priority at the hospital's side. And at times deploying a new protocol exceeds what the nursing team can handle, or right now they have another priority. For example, they are upgrading their Epic system; so those represent some practical obstacles we encounter, yet we think that eventually, thanks to the strong guideline recommendation plus this clinical value and evidence that will keep being generated, we ought to get past those obstacles; regarding the 510(k) headcap, I think you mean the neonatal and headcap. The key clearance we obtained there relative to the earlier neonate headcap is that with the earlier version, we had the label of approved for all ages; and through our pilot, we discovered that our physician and nurses wanted the FDA clearance to be even more specific — that it is cleared for preterm as well as term neonate — since they are extremely protective of this vulnerable population; so, our newest headcap is cleared for both preterm as well as term the neonatal population; so, this is truly a great manifestation, an example of our strategy. While doing pilots, we actually discovered things we did not anticipate when we rolled out the product; so, we see this recently approved or cleared headcap as the product that will be ready for full commercialization once we receive the clearance of neonatal clarity.
Nice work on yet another solid quarter. Jane, I believe you mentioned that Ceribell point-of-care EEG has reached roughly 10% of U.S. acute care hospitals. Based on what we hear from the customer base, the word of mouth keeps getting louder, the buzz keeps building, and the library of clinical evidence plus the cost-effective data keeps expanding. I was hoping to use that as a lead-in to a question: can you give us some quantitative or qualitative color on where the new customer account pipeline, or funnel, stands right now compared with the start of the year? And also help us think about the potential for account growth in 2026?
Yes, Josh, what shows up in our active account base is launched accounts, meaning the customer is fully trained and live. Naturally, we track things earlier than that too — we track when a purchase order comes in, and we track the different stages of engagement that occur before a purchase order. Without giving specific figures, I can say that this number — the funnel — is expanding, and that expansion directly reflects both the investments we've made in our commercial org over the past year and, I believe, a growing appreciation of the need for this technology that increases by the day.
I was simply trying to get a clearer picture of where Ceribell stands when it comes to IDNs, or health care systems. Also, has the business gained anything from certain IDNs sort of establishing best practices choices or standard of care across their network? Or does that chance still lie ahead for Ceribell? Perhaps just walk us through how you're situated relative to how many IDNs are active in the United States.
Thanks, Josh. Indeed, what we've observed is that working alongside hospital systems has proven a robust growth driver going back to earlier years, the present one included; and we believe there's possibly an even larger opening waiting for us going forward. My sense is that in earlier times, particularly several years ago when our scale was far smaller, we typically wouldn't approach an IDN at the headquarter level, given how small we were. Our focus was more on engaging each hospital individually as we grew to be present in more than 600 hospitals across the U.S. Now we're assembling our hospital system sales team, plus the whole sales team — coaching everyone on our sales force to consider not just a single hospital but truly to consider sales at the hospital system level. That calls for what we term bottom-up and top-down sales coordination. It's really only this year that we began doing this in a systematic way. So we expect to keep carrying this out and seize the opportunity in front of us, turning into an even stronger partner for our customers.
Also, nice work on how you said that name. Let me begin by saying that when I look at the guidance, it strikes me as quite wide. The bottom end comes in at roughly 23% year-over-year, while the top end sits at 25% or 35% year-over-year. There are several things I want to ask about here. To begin, what accounts for the difference between the lower bound and the upper bound? Given that we're nearing the close of the year, that guidance range seems quite wide to me. That's my first question, and I have several more after it.
Yes. Bill, our approach to guidance hasn't changed, I'd say. Since we've only been a public company for a year, we recognize how important it is to offer figures that we're highly confident we can deliver, and that shapes how we approach guidance. So when we have things we're aware of or believe in — Q4 seasonality being stronger than Q3, for instance — in setting the low end of the range, we aim to be very conservative and basically remove all the uncertainty. So. I think — what I'd take from that range is really that it reflects risk calibration and our commitment to giving numbers we have an extremely high level of confidence in.
All right. Then I'd just like to — after the IPO, one item you did involved taking a large portion of that and putting it toward the sales force. Any update on where things stand today with the TMs and the CAMs? And then, you recorded a rise, I believe essentially 31 net new active accounts on a sequential basis. That's the largest figure we've witnessed in quite a while; it's clearly moving upward. Is that simply a result of the new reps who came aboard? What exactly is driving that this quarter?
When it comes to the commercial infrastructure, no fundamental adjustments have been made to our strategy since the prior quarter. The number of territories we've planned remains approximately the same, in the mid-50s at present on the TM side. On the CAM side of the business, we have invested and will keep investing, since that part of the org expands at a rate roughly consistent with growth of the account base. So that side is fully staffed, though it will keep expanding. I think we're likewise examining opportunities to put money in places that speed up growth further. And the response James gave to an earlier question, I think, points to one area we're watching quite closely, namely IDN level systems. Regarding the account additions, we're clearly quite happy with what happened this quarter. I know there's a substantial sort of emotional gap between the 29 we posted last quarter and the 31 from a couple of quarters back. But I'd regard that mostly as falling within the sort of range of anticipated results here, and we absolutely expected the people we bring on to begin producing as we move into 2826.
All right. Then I believe Robbie posed the question that your revenue growth has been quite robust. We have not observed any leverage in the P&L. And I think a question that comes to us from investors is whether that is something we're, like — I realize guidance hasn't been provided by you yet, but is there any reason we won't begin seeing it at some point in the coming year?
The sole reason you would anticipate — my anticipation would be that we don't see it, is if a strategic choice gets made by us because a profound growth opportunity is perceived to truly invest in the OpEx so that growth can be captured. And at the moment we make that choice, it will be communicated clearly by us to the Street, ensuring it isn't a surprise.
All right. Is there anything new regarding competitors? The second thing people ask about constantly is just rivalry. What's happening out there in the market? Compared with 6 or 12 months back, are we now dropping more accounts, or gaining more of them? Also, what's the latest on the intellectual property lawsuit? What happens next?
Sure. When it comes to competing, I'd say during Q1 and Q2, competitive activity rose quite a bit, which we've noted in the past; as for Q3, I'd say nothing major has shifted. We keep observing more competitive moves out there. That said, I'd argue our results in 2025 tell the story on their own. Each quarter, we exceeded guidance and lifted it, which demonstrates that rivals aren't really hurting our results in any meaningful way. What lets us pull this off isn't just capitalizing on how much better our product is, along with our clinical evidence and cybersecurity — we're also picking up plenty of insight into what competitors are doing and putting tactics and plans into action to handle it. As for the ITC case, as investors, or perhaps you, have likely noticed, the ITC laid out the key dates prior to the shutdown. Back then, the expected ruling was September of next year, with a final decision in January 2027; given the government shutdown, we expect a certain amount of slippage there, and we also figure the ITC will revise that schedule once the government starts up again.
All right. Then one final item from me. I believe you brought up the move to Vietnam on the manufacturing side. We'll begin seeing that effect during Q4. I believe you said that's going to push gross margin into the mid-80s. Does all of that land in the quarter? Or is it more that margins step down over the course of this year in Q4, and then reach that mid-80s level in the following year? How should we frame the cadence there? Your line is live.
Hi. So for Q4, during the first portion of the quarter we'll depend on pre-tariff inventory, and afterward, for the rest of the quarter, solely on China inventory, since essentially that inventory was obtained before Vietnam was operational. So Vietnam has no effect on this quarter. As we head into next year, what you'll observe is China inventory we bought at a higher tariff rate blended together with Vietnam inventory at a lower tariff rate as things stand, and that ought to show up as a continuation of the mid-80% gross margin in the next year.
First off, I was hoping you might go a little deeper on the VA channel — walk us through a few of the accounts you have now, plus the ones that have expanded, and what you're anticipating there. How does that shape Q4 and the coming year when it comes to growth tied specifically to VA?
Sure. So even though we aren't able to, and don't, give out the exact figures for VA or for any particular hospital system, I'm genuinely thrilled and can share more of what's possible to say about VA. The VA runs a highly disciplined approach: they start with a pilot, then bring it out in stages in an organized way. As things stand today, the initial handful of pilots have gone extremely well. The doctors and the administrators at the VA both clearly recognized and felt firsthand the value that our system provides, from a clinical standpoint and a financial one. So we've now got confirmation that we'll expand to the first bigger group of VA accounts over the coming 2 quarters. That makes this one of the biggest top-down rollouts ever undertaken in Ceribell's history. That's the part we're really enthusiastic about. It represents a major win, not just for the company, but for the veterans we serve, who face the risk of seizures.
All right, understood. And as a second question, I recall you discussed the headcap and neonatals earlier, but you mentioned something regarding hardware utilization without clarity that occurred in Q3. Would you mind elaborating on that for us a bit more?
Sure. At this stage, it's probably too early to discuss utilization at the account level for neonate, since the pilot we're focused on really centers on the population discussion, verifying signal quality, and verifying ease of use. Given that nature, it doesn't perfectly mirror what actual commercial clinical usage would look like. What we can share, though, is that it's been very well received. We already have some case studies where the physicians and nurses significantly helped the patient, whether by detecting seizure early or avoiding unnecessary medication for the patient, which matters greatly for patients' outcome. So we're excited to potentially bring the full product, from hardware with Clarity, to market in 2026.
This is Elaine calling in for Jason. Based on our calculations, utilization increased compared to the same period last year, even with that difficult comparison created by stocking during 3Q '24. So I wanted to ask: how much would utilization have risen if we set aside the effect of that stocking? Also, did the normal seasonal pattern show up this quarter too?
Without those purchases—the extra buying that happened in Q3—the comparison for year-over-year growth this quarter would have ended up looking a lot like what we recorded for year-over-year growth in Q1 and Q2. On the seasonality question: yes, naturally, we won't have certainty until Q4 is behind us. Still, looking at it on a sequential basis, Q1 came in quite strong, while Q2 and Q3 were softer sequentially. That pattern matches precisely what has occurred over the past 2 years. Obviously we remain only a few years into this commercial journey, yet nothing about this year has caught us off guard regarding how trends unfolded from quarter to quarter.
And as my second question, I was hoping you might give us additional — apologies, additional insight into how utilization is trending; is it specific departments that are fueling the higher utilization? For example, are you noticing more within the ICU or the ED? And I'm aware you mentioned the use cases somewhat.
Yeah. On the whole, what we're seeing is actually fairly widespread growth drivers. So, ranging from departmental expansion to protocolization and also past the ICU and ED into the floor and step-down units. And in particular, growth looks a touch even more robust in the emergency department than in the ICU, since EDs generally are penetrated even less. So that's the big picture, though no individual driver stands out as being responsible for most of the growth.
Thanks. So, I appreciate all of you being here and paying attention on this call. Once again, we feel a great deal of excitement and pride regarding what we got done during Q3, and we can't wait to tell you about how we did in the upcoming quarter as well as the ones after that. Thanks.
This concludes the meeting. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete CeriBell, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to CeriBell, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.